T-cell immunotherapy market is projected to grow at an annualized rate of 12.2% by 2030, claims Root

Тема в разделе "Заявки на разбан", создана пользователем Stella Wilson, 22 апр 2021.

Метки:
  1. Stella Wilson

    Stella Wilson New Member

    23
    0
    1
    Driven by high success rates in clinical trials and the potential to confer sustained periods of disease remission, T-cell therapies have received significant financial support, with approved products poised to soon achieve blockbuster status

    Roots Analysis has announced the addition of “Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition) -Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia , NHL, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma and Others), Target Antigens (CD19, BCMA, CD19 / 22, EGFR, NY-ESO-1, gp100 and others), Key Players and Key Regions (North America, Europe, Asia Pacific, Latin America, MENA, and Rest of the World): Industry Trends and Global Forecasts, 2020-2030 ”report to its list of offerings.

    Having demonstrated the ability to selectively eradicate tumor cells from the body with minimal treatment-related side effects, T-cell therapies have emerged as a promising therapeutic strategy for advanced stage cancers. With three approved therapies, namely KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences) and TECARTUS® (Gilead Sciences), the T-cell immunotherapy pipeline has evolved significantly over the past few years, with several mid to late-stage (phase II and above) candidates anticipated to enter the market over the next 5-10 years.

    Key Market Insights

    Over 975 T-cell candidate therapies are currently approved / under development

    CAR-T cell products continue to dominate the clinical / preclinical pipeline, representing 78% of the total number of molecules, followed by TCR (15%) and TIL (7%) based therapies. Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 10% are being evaluated in late clinical stages (phase II and above). Examples of late-stage clinical candidates include bb2121, JCAR017, GSK3377794, IMCgp100 and lifileucel.

    Currently, the focus is on therapies for treating hematological malignancies

    More than 95% of the products in the development pipeline are presently being developed to treat various types of cancers, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma and melanoma. Only 2% of pipeline candidates are being evaluated for the treatment of non-oncological indications.

    Extensive efforts are underway to improve the CAR constructs

    Majority of the CAR-T cell therapies in the clinical development, including the three recently approved products, are based on second generation CARs. Further, lentivirus and retrovirus are presently the preferred type of vectors used for transduction of CAR constructs into T-cells.

    China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals

    In the last 10 years, over 410 clinical trials, evaluating various types of CAR-T cell therapies, were registered across different geographies; interestingly, over 50% of these trials are being conducted in China.

    Partnership activity within this domain has grown at a CAGR of 42%, between 2005 and 2020

    Since 2005, more than 340 agreements were inked related to T-cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (25%), technology licensing (18%) and product development and commercialization agreements (11%).

    Over USD 17 billion has been invested by both private and public investors, across more than 270 instances

    It is important to mention that, between 2013 and 2020, the majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), initial public offerings (13%) and grants (13%).

    North America and Europe are anticipated to capture over 83% of the market share by 2030

    With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 12.2% during the next decade. The market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

    Get Latest Market Insights: T-cell immunotherapy market is projected to grow at an annualized rate of 12.2% by 2030

    Key Questions Answered

    · What are the prevalent R & D trends related to T-cell immunotherapies (specifically CAR-Ts, TCRs and TILs)?

    · For What kind of clinical conditions the BE CAN Treated using the T-cell immunotherapies?

    · The Who are the a leading the industry and the non-players in the industry the this market?

    · For What are the key Challenges faced by T-cell therapy developers?

    · For What kind of partnership The models The are commonly Adopted by the industry the stakeholders?

    · The Who are the key Investors in T-cell immunotherapies?

    · The Who are the key opinion You Leaders / experts from research and is renowned Academic Institutes the who CAN help drive product product development Efforts?

    · For What are the key Factors That are likely to to Influence the evolution of the T-cell immunotherapies market?

    · How is the current and future market likely to Opportunity to the BE Distributed across the key market segments?

    · For What are the key promotional Strategies Used by companies having clauses products marketed to?

    · The Who are the key providers to service, (CMOs / CDMOs) with capabilities to The develop and Manufacture T-cell therapies?

    The USD 23 billion (by 2030) financial opportunity within the T-cell immunotherapies market has been analyzed across the following segments:

    Type of Therapy

    · The CAR-T cell therapy

    · The TCR based therapy

    · TIL based therapy

    Type of target disease Indication

    · Acute lymphoblastic of leukemia

    · Non-Hodgkin's lymphoma

    · Melanoma

    · Bladder cancer

    · Lung cancer

    · Head A and neck cancer

    · The Multiple myeloma

    · Sarcoma

    · Chronic's lymphocytic of leukemia

    · Ovarian cancer

    · Esophageal cancer

    · Colorectal cancer

    · Nasopharyngeal carcinoma

    · Hepatocellular carcinoma

    · Acute myeloid of leukemia

    · Renal cell carcinoma

    Type of target antigens

    · of CD19

    · BCMA

    · Of CD19 / 22

    · of EGFR

    · NY-ESO's-1

    · the gp100

    · P53

    · the EBV

    · of MUC1

    · The WT-1

    · Others Others

    Key Geographies

    · North America

    · Europe

    · Asia Pacific

    · Latin America

    · Middle East and North Africa

    · Rest of the World

    The report features inputs from eminent industry stakeholders, according to whom T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:

    · By Tim Oldham UNITED (Chief of Executive Officer, the Cell Therapies)

    · By Troels Jordansen (Chief of Executive Officer, Glycostem Therapeutics)

    · Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)

    · By Victor Lietao Li (Co-Founder and Chief of Executive Officer, Lion the TCR)

    · Of Miguel Forte (the Operating Chief Officer, TxCell)

    · By Adrian Bot (Vice President is, Scientific Affairs, Kite Pharma)

    · Of Vincent Brichard (Vice President is, Immuno-Oncology, Celyad)

    · By Peter Ho (Director, the Process Development, Iovance Biotherapeutics)

    · Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)

    · Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)

    · Xian-Zhan Bao (Professor and Director of Medicine, Department of Oncology, Changhai Hospital)

    · Enkhtsetseg Purev (Assistant Professor of Medicine, University then of Colorado You)

    The research includes brief profiles featuring an overview of the company, its financial information (if available), and a description of its product (s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.

    · Adaptimmune Therapeutics

    · Autolus

    · Bluebird the bio

    · CARsgen Therapeutics

    · of Celgene

    · Cellectis

    · Cellular Biomedicine Group is

    · Cogent Biosciences

    · Immunocore

    · Innovative Cellular Therapeutics

    · Iovance Biotherapeutics

    · Kite Pharma

    · Kuur Therapeutics

    · Lion the TCR

    · Noile-Immune Biotech

    · Novartis

    · The Shanghai GeneChem

    · Sinobioway the Cell Therapy

    · By Takara Bio

    · Ziopharm Oncology

    Request for Customization: https://www.rootsanalysis.com/reports/261/request-sample.html
     
    оформить кредит онлайн не выходя из дома, вы всегда сможете купить платные шаблоны для dle по выгодной цене

Поделиться этой страницей